Early Access to Medicine Scheme Up and Running
Since the program's launch in April 2014, three 'promising innovative medicine' (PIM) designations have already been granted as part of the UK's Early Access to Medicines Scheme (EAMS). The venture, from the UK's Medicines and Healthcare Products Regulatory Agency (MHRA), is aimed to speed up access to as yet unlicensed medicines where there is a high unmet medical need.
PIM designation is the first in a two-step process, which recognizes a product as a good candidate fo...
To continue reading this story get free access